MedTrace Logo

Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection

NCT00520949 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2009-04-08

No results posted yet for this study

Summary

Triple therapy, a combination of proton pump inhibitor with two antibiotics, is the gold standard for anti-Helicobacter pylori treatment. Usual antibiotics are clarithromycin, and either amoxicillin or one of the nitroimidazoles (metronidazole). However, there is an increasing evidence of H. pylori resistance to classical triple therapy. Another reason for this failure being low patient compliance with treatment. A regimen useful in one geographical area may not be effective or practical in another area. The aim of this study was to eradicate H. pylori infection resistant to triple therapy, establish the efficacy and safety of a 14-day therapeutic regimen to eradicate of H. pylori in patients who have failed with the classical triple therapy (omeprazole, clarithromycin and amoxicillin) given for 14 days.

Conditions

  • Treatment of Helicobacter Pylori

Interventions

DRUG

Augmentin (Amoxicillin-clavulanic)

Amoxicillin-clavulanic acid 1 gram b.i.d

DRUG

Furoxone (furazolidone)

furazolidone 200 mg b.i.d

DRUG

Cebes (colloidal bismuth subcitrate)

colloidal bismuth subcitrate 240 mg b.i.d

DRUG

Esso (esomeprazole)

esomeprazole 40 mg b.i.d for 14 days

Sponsors & Collaborators

  • Aga Khan University

    lead OTHER

Principal Investigators

  • Zaigham Abbas, FACG · Aga Khan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520949 on ClinicalTrials.gov